Interleukin-6 in aging and chronic disease: a magnificent pathway.

By M. Maggio, Jack M. Guralnik, D. Longo, Luigi Ferrucci. The journals of gerontology. Series A, Biological sciences and medical sciences, 2006

679 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Aging, frailty and age-related diseases (2010, background): “This state of ‘‘Inflamm-aging’’ seems to manifest by an increase in the IL-6 level which may be a reliable marker for functional disability and a predictor of frailty with subsequent disability and mortality in the elderly (Maggio et al. 2006).”
Inflammatory Networks during Cellular Senescence: Causes and Consequences (2010, background): “interleukin (IL)-6 and tumor necrosis factor (TNF)α) in aged individuals (>50 years of age), compared to younger individuals [5,6].”
Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. (2014, background): “IL-6 is arguably the most prominent cytokine that is shared across age-related pathologies having a strong chronic inflammatory component (29).”
Aging in COVID-19: Vulnerability, immunity and intervention (2020, neutral): “These observations have led to the ongoing therapeutic development targeting IL-6, a cytokine mediator that is considered as a hallmark of inflammaging (Franceschi et al., 2000, 2017; Maggio et al., 2006).”